Skip to main content
letter
. 2020 Jul 4;416:117011. doi: 10.1016/j.jns.2020.117011

Fig. 1.

Fig. 1

(a) CD3+ and CD3 + CD4+ lymphocyte count after start of therapy with fingolimod until the hospitalization for Covid-19 in case 1 (b) anti spike protein S1 receptor binding domain (S1RBD) and anti-nucleocapsid (NP) IgG response to SARS-CoV-2 in patient 1 and 2 detected at 7,21,28,35 days after diagnosis. Dotted line: Cut off of anti-NP IgG positivity (=0.199). Continuous line: Cut off of anti-S1RBD IgG positivity (=1.000). Od450: optical density measurements using a microplate reader with a 450 nm filter.